<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02538926</url>
  </required_header>
  <id_info>
    <org_study_id>9459</org_study_id>
    <secondary_id>NCI-2015-01402</secondary_id>
    <secondary_id>CC9459</secondary_id>
    <secondary_id>9459</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT02538926</nct_id>
  </id_info>
  <brief_title>Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma</brief_title>
  <official_title>A Phase II Study of Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin Plus Asparaginase (DA-EPOCH-A) for Adults With Acute Lymphoblastic Leukemia/Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well etoposide, prednisone, vincristine sulfate,&#xD;
      cyclophosphamide, and doxorubicin hydrochloride with asparaginase work in treating patients&#xD;
      with acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy, such&#xD;
      as etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin&#xD;
      hydrochloride, work in different ways to stop the growth of cancer cells, either by killing&#xD;
      the cells, by stopping them from dividing, or by stopping them from spreading. Asparaginase&#xD;
      breaks down the amino acid asparagine and may block the growth of tumor cells that need&#xD;
      asparagine to grow. Giving combination chemotherapy with asparaginase may work better in&#xD;
      treating patients with acute lymphoblastic leukemia or lymphoblastic lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the efficacy of dose-adjusted etoposide, prednisone, vincristine sulfate,&#xD;
      cyclophosphamide, and doxorubicin hydrochloride plus asparaginase (DA-EPOCH-A) in adults with&#xD;
      acute lymphoblastic leukemia/lymphoma (ALL).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate the safety and feasibility of this regimen.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive etoposide, doxorubicin hydrochloride, and vincristine sulfate intravenously&#xD;
      (IV) continuously over days 1-4, cyclophosphamide IV over 1 hour on day 5, and prednisone&#xD;
      orally (PO) twice daily (BID) on days 1-5. Patients also receive asparaginase intramuscularly&#xD;
      (IM) or IV over 1-2 hours every 2-3 days, beginning day 7 of each course. Patients who are&#xD;
      cluster of differentiation (CD)20 positive and Philadelphia chromosome negative also receive&#xD;
      rituximab IV on day 1 or 5. Patients who are Philadelphia chromosome positive also receive&#xD;
      imatinib mesylate PO on days 1-14. Treatment repeats every 21 days for up to 8 courses in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 3 months for 2 years and&#xD;
      then every 6 months for 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Drugs unavailable&#xD;
  </why_stopped>
  <start_date type="Anticipated">July 1, 2018</start_date>
  <completion_date type="Anticipated">July 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete minimal residual disease response rate</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>A Simon two-stage optimum design will be used to define success of this treatment in the two subgroups of patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall response rate (complete response + partial response)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>A Simon two-stage optimum design will be used to define success of this treatment in the two subgroups of patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From time of initiation of study therapy to up to 5 years</time_frame>
    <description>A Simon two-stage optimum design will be used to define success of this treatment in the two subgroups of patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>From time of initiation of study therapy to up to 5 years</time_frame>
    <description>A Simon two-stage optimum design will be used to define success of this treatment in the two subgroups of patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events, graded using the National Cancer Institute Common Terminology Criteria for Adverse Events</measure>
    <time_frame>Up to 30 days post-treatment, or until patient receives an alternative anti-cancer therapy, whichever date comes first</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>B Acute Lymphoblastic Leukemia</condition>
  <condition>B Lymphoblastic Lymphoma</condition>
  <condition>Recurrent Adult Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent B Lymphoblastic Lymphoma</condition>
  <condition>Recurrent T Lymphoblastic Leukemia/Lymphoma</condition>
  <condition>Refractory B Lymphoblastic Lymphoma</condition>
  <condition>Refractory T Lymphoblastic Lymphoma</condition>
  <condition>T Acute Lymphoblastic Leukemia</condition>
  <condition>T Lymphoblastic Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment (DA-EPOCH-A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive etoposide, doxorubicin hydrochloride, and vincristine sulfate IV continuously over days 1-4, cyclophosphamide IV over 1 hour on day 5, and prednisone PO BID on days 1-5. Patients also receive asparaginase IM or IV over 1-2 hours every 2-3 days, beginning day 7 of each course. Patients who are CD20 positive and Philadelphia chromosome negative also receive rituximab IV on day 1 or 5. Patients who are Philadelphia chromosome positive also receive imatinib mesylate PO on days 1-14. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asparaginase</intervention_name>
    <description>Given IM or IV</description>
    <arm_group_label>Treatment (DA-EPOCH-A)</arm_group_label>
    <other_name>ASP-1</other_name>
    <other_name>Asparaginase II</other_name>
    <other_name>Asparaginase-E.Coli</other_name>
    <other_name>Colaspase</other_name>
    <other_name>Elspar</other_name>
    <other_name>Kidrolase</other_name>
    <other_name>L-Asnase</other_name>
    <other_name>L-ASP</other_name>
    <other_name>L-Asparaginase</other_name>
    <other_name>L-Asparagine Amidohydrolase</other_name>
    <other_name>Laspar</other_name>
    <other_name>Lcf-ASP</other_name>
    <other_name>Leucogen</other_name>
    <other_name>Leunase</other_name>
    <other_name>MK-965</other_name>
    <other_name>Paronal</other_name>
    <other_name>Re-82-TAD-15</other_name>
    <other_name>Serasa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (DA-EPOCH-A)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (DA-EPOCH-A)</arm_group_label>
    <other_name>5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI)</other_name>
    <other_name>ADM</other_name>
    <other_name>Adriacin</other_name>
    <other_name>Adriamycin</other_name>
    <other_name>Adriamycin Hydrochloride</other_name>
    <other_name>Adriamycin PFS</other_name>
    <other_name>Adriamycin RDF</other_name>
    <other_name>ADRIAMYCIN, HYDROCHLORIDE</other_name>
    <other_name>Adriamycine</other_name>
    <other_name>Adriblastina</other_name>
    <other_name>Adriblastine</other_name>
    <other_name>Adrimedac</other_name>
    <other_name>Chloridrato de Doxorrubicina</other_name>
    <other_name>DOX</other_name>
    <other_name>DOXO-CELL</other_name>
    <other_name>Doxolem</other_name>
    <other_name>Doxorubicin.HCl</other_name>
    <other_name>Doxorubin</other_name>
    <other_name>Farmiblastina</other_name>
    <other_name>FI 106</other_name>
    <other_name>FI-106</other_name>
    <other_name>hydroxydaunorubicin</other_name>
    <other_name>Rubex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (DA-EPOCH-A)</arm_group_label>
    <other_name>Demethyl Epipodophyllotoxin Ethylidine Glucoside</other_name>
    <other_name>EPEG</other_name>
    <other_name>Lastet</other_name>
    <other_name>Toposar</other_name>
    <other_name>Vepesid</other_name>
    <other_name>VP 16-213</other_name>
    <other_name>VP-16</other_name>
    <other_name>VP-16-213</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib Mesylate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (DA-EPOCH-A)</arm_group_label>
    <other_name>CGP 57148</other_name>
    <other_name>CGP57148B</other_name>
    <other_name>Gleevec</other_name>
    <other_name>Glivec</other_name>
    <other_name>STI 571</other_name>
    <other_name>STI-571</other_name>
    <other_name>STI571</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (DA-EPOCH-A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (DA-EPOCH-A)</arm_group_label>
    <other_name>.delta.1-Cortisone</other_name>
    <other_name>1, 2-Dehydrocortisone</other_name>
    <other_name>Adasone</other_name>
    <other_name>Cortancyl</other_name>
    <other_name>Dacortin</other_name>
    <other_name>DeCortin</other_name>
    <other_name>Decortisyl</other_name>
    <other_name>Decorton</other_name>
    <other_name>Delta 1-Cortisone</other_name>
    <other_name>Delta-Dome</other_name>
    <other_name>Deltacortene</other_name>
    <other_name>Deltacortisone</other_name>
    <other_name>Deltadehydrocortisone</other_name>
    <other_name>Deltasone</other_name>
    <other_name>Deltison</other_name>
    <other_name>Deltra</other_name>
    <other_name>Econosone</other_name>
    <other_name>Lisacort</other_name>
    <other_name>Meprosona-F</other_name>
    <other_name>Metacortandracin</other_name>
    <other_name>Meticorten</other_name>
    <other_name>Ofisolona</other_name>
    <other_name>Orasone</other_name>
    <other_name>Panafcort</other_name>
    <other_name>Panasol-S</other_name>
    <other_name>Paracort</other_name>
    <other_name>PRED</other_name>
    <other_name>Predicor</other_name>
    <other_name>Predicorten</other_name>
    <other_name>Prednicen-M</other_name>
    <other_name>Prednicort</other_name>
    <other_name>Prednidib</other_name>
    <other_name>Prednilonga</other_name>
    <other_name>Predniment</other_name>
    <other_name>Prednisonum</other_name>
    <other_name>Prednitone</other_name>
    <other_name>Promifen</other_name>
    <other_name>Servisone</other_name>
    <other_name>SK-Prednisone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (DA-EPOCH-A)</arm_group_label>
    <other_name>BI 695500</other_name>
    <other_name>C2B8 Monoclonal Antibody</other_name>
    <other_name>Chimeric Anti-CD20 Antibody</other_name>
    <other_name>IDEC-102</other_name>
    <other_name>IDEC-C2B8</other_name>
    <other_name>IDEC-C2B8 Monoclonal Antibody</other_name>
    <other_name>MabThera</other_name>
    <other_name>Monoclonal Antibody IDEC-C2B8</other_name>
    <other_name>PF-05280586</other_name>
    <other_name>Rituxan</other_name>
    <other_name>Rituximab Biosimilar BI 695500</other_name>
    <other_name>Rituximab Biosimilar PF-05280586</other_name>
    <other_name>Rituximab Biosimilar RTXM83</other_name>
    <other_name>RTXM83</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine Sulfate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (DA-EPOCH-A)</arm_group_label>
    <other_name>Kyocristine</other_name>
    <other_name>Leurocristine Sulfate</other_name>
    <other_name>Leurocristine, sulfate</other_name>
    <other_name>Oncovin</other_name>
    <other_name>Vincasar</other_name>
    <other_name>Vincosid</other_name>
    <other_name>Vincrex</other_name>
    <other_name>Vincristine, sulfate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have a confirmed diagnosis of either B- or T-cell acute lymphoblastic&#xD;
             leukemia or lymphoblastic lymphoma that is either:&#xD;
&#xD;
               -  Arm A: Initially diagnosed at age 40 or later, OR&#xD;
&#xD;
               -  Arm B: Relapsed after or failed to respond to &gt;= 1 previous chemotherapy regimen&#xD;
&#xD;
          -  The regimen under study must constitute a reasonable therapeutic option&#xD;
&#xD;
          -  Presence of &gt;= 5% abnormal blasts in the bone marrow&#xD;
&#xD;
          -  Patients with prior allogeneic hematopoietic cell transplantation (HCT) must be at&#xD;
             least 90 days post-HCT and must be on =&lt; 20 mg of prednisone (or equivalent dose of an&#xD;
             alternative corticosteroid) for treatment/prevention of graft-vs-host disease&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 x institutional upper limit of normal (ULN; unless attributable&#xD;
             to Gilbert's disease or other causes of inherited indirect hyperbilirubinemia, at&#xD;
             which point total bilirubin must be =&lt; 2.5 x ULN)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase&#xD;
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])&#xD;
             =&lt; 3.0 x institutional ULN&#xD;
&#xD;
          -  Note: Patients with liver test abnormalities attributable to hepatic involvement by&#xD;
             ALL will be permitted if the total bilirubin is =&lt; 3.0 x ULN and ALT/AST are =&lt; 5.0 x&#xD;
             ULN&#xD;
&#xD;
          -  Creatinine =&lt; 1.5 mg/dL; however, patients with a creatinine &gt; 1.5 mg/dL but with a&#xD;
             calculated creatinine clearance of &gt; 60 ml/min, as measured by the Modification of&#xD;
             Diet in Renal Disease (MDRD) equation, will be eligible&#xD;
&#xD;
          -  Measurement of left ventricular ejection fraction (LVEF) should be performed in&#xD;
             patients with prior anthracycline exposure or known history of arrhythmia or&#xD;
             structural heart disease; in these cases, LVEF must be &gt;= 40%&#xD;
&#xD;
          -  As patients with ALL frequently have cytopenias, no hematologic parameters will be&#xD;
             required for enrollment or to receive the first cycle of treatment; however, adequate&#xD;
             recovery of blood counts will be required to receive subsequent cycles&#xD;
&#xD;
          -  Per good clinical practice, any toxicity related to prior therapies that, in the&#xD;
             opinion of the investigator, would potentially be worsened with DA-EPOCH-A +/-&#xD;
             imatinib (imatinib mesylate) +/- rituximab, should be resolved to grade 1 or less&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2&#xD;
&#xD;
          -  Women of childbearing potential must have a negative pregnancy test and must agree to&#xD;
             the use of effective contraception while on treatment; men must also agree to the use&#xD;
             of effective contraception while on treatment&#xD;
&#xD;
          -  Ability to give informed consent and comply with the protocol&#xD;
&#xD;
          -  Anticipated survival of at least 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with Burkitt lymphoma/leukemia&#xD;
&#xD;
          -  Patients must not have received chemotherapy within 14 days of enrollment, with the&#xD;
             two following exceptions:&#xD;
&#xD;
               -  Routine systemic maintenance therapy (e.g., Abelson murine leukemia viral&#xD;
                  oncogene homolog 1 [ABL] kinase inhibitor, methotrexate, 6-mercaptopurine,&#xD;
                  vincristine, etc.) and intrathecal/intraventricular therapy&#xD;
&#xD;
               -  Systemic therapy for the acute management of hyperleukocytosis or acute symptoms&#xD;
                  (e.g., corticosteroids, cytarabine, etc.)&#xD;
&#xD;
          -  May not have prior malignancies unless the expected survival is at least 2 years&#xD;
&#xD;
          -  For patients with Philadelphia chromosome positive (Ph+) ALL, they must not have&#xD;
             progressed within 3 months of receiving imatinib or have a documented ABL kinase&#xD;
             mutation known to confer resistance to imatinib (e.g., T315I)&#xD;
&#xD;
          -  Patients with persistent grade 2 or higher peripheral sensory or motor neuropathy of&#xD;
             any cause&#xD;
&#xD;
          -  Patients with isolated extramedullary disease or with parenchymal central nervous&#xD;
             system (CNS) disease&#xD;
&#xD;
          -  Known hypersensitivity or intolerance to any of the agents under investigation&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV) positive or evidence of infection with hepatitis B&#xD;
             or C virus, as defined by any of the following criteria (if patients have not&#xD;
             previously been tested for the following, these will be conducted during screening):&#xD;
&#xD;
               -  HIV antibody positive&#xD;
&#xD;
               -  Hepatitis B surface antigen or core antibody positive&#xD;
&#xD;
               -  Hepatitis C antibody positive&#xD;
&#xD;
          -  Other medical or psychiatric conditions that in the opinion of the investigator would&#xD;
             preclude safe participation in the protocol&#xD;
&#xD;
          -  May not be pregnant or nursing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ryan Cassaday</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>August 31, 2015</study_first_submitted>
  <study_first_submitted_qc>August 31, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2015</study_first_posted>
  <last_update_submitted>November 9, 2018</last_update_submitted>
  <last_update_submitted_qc>November 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cortisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>Podophyllotoxin</mesh_term>
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

